MRI-US Registration Using Label-driven Weakly-supervised Learning for Multiparametric MRI-guided HDR Prostate Brachytherapy

Validation of MRI to TRUS registration for HDR prostate brachytherapy Running head title: MRI to TRUS registration for prostate brachytherapy

Label-driven weakly-supervised learning for multimodal deformable image registration

Spatially aligning medical images from different modalities remains a challenging task, especially for intraoperative applications that require fast and robust algorithms. We propose a weakly-supervised, label-driven formulation for learning 3D voxel correspondence from higher-level label correspondence, thereby bypassing classical intensity-based image similarity measures. During training, a c...

Multiparametric MRI-Targeted TRUS Prostate Biopsies Using Visual Registration

Prebiopsy multiparametric prostate MRI (mp-MRI), followed by transrectal ultrasound-guided (TRUS-G) target biopsies (TB) of the prostate is a key combination for the diagnosis of clinically significant prostate cancers (CSPCa), to avoid prostate cancer (PCa) overtreatment. Several techniques are available for guiding TB to the suspicious mp-MRI targets, but the simplest, cheapest, and easiest t...

Dosimetric and Radiobiological Evaluation of Multiparametric MRI-guided Dose Painting in radiotherapy of Prostate Cancer

Introduction: Radiotherapy is one of the treatment options for locally advanced prostate cancer, however with standard radiation doses it is not always very effective. One of the strategies to improve the efficiency of radiotherapy is increasing the dose. In this study to increase tumor local control rates a new radiotherapy method, known as dose painting (DP) was investigated....

Multiparametric MRI in Biopsy Guidance for Prostate Cancer: Fusion-Guided

Prostate cancer (PCa) is the most common solid-organ malignancy among American men and the second most deadly. Current guidelines recommend a 12-core systematic biopsy following the finding of an elevated serum prostate-specific antigen (PSA). However, this strategy fails to detect an unacceptably high percentage of clinically significant cancers, leading researchers to develop new, innovative ...